Results 181 to 190 of about 195,924 (307)

Effect of Interval Between Neoadjuvant Immunochemotherapy and Radical Resection of Non‐Small Cell Lung Cancer: A Multicenter, Retrospective Cohort Study

International Journal of Cancer, EarlyView.
The optimal timing of surgery after neoadjuvant immunochemotherapy (NICT) for locally advanced non‐small cell lung cancer (NSCLC) remains unclear. In this retrospective investigation, the impact of time interval on outcome was assessed among NSCLC patients who completed NICT before undergoing radical resection.
Jiayi Wang, Pingping Song, Yong Ge, Haitang Yang, Shuyuan Li, Ran Ma, Tianyue Ma, Shoujie Feng, Cheng Zhang, Teng Sun, Feng Yao, Jun Yi, Hao Zhang   +12 more
wiley   +1 more source

The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer

International Journal of Cancer, EarlyView.
Neoadjuvant endocrine therapy (NET) can help prevent metastases and improve survival in patients with hormone receptor‐positive (HR+) breast cancer. Identifying which HR+ patients will benefit from NET, however, remains challenging. Here, in a patient cohort in the Netherlands, the authors evaluated tumor‐stroma ratio (TSR) and magnetic resonance ...
Layla Andour, Sophie C. Hagenaars, Anne Florine de Groot, Elly M. M. Krol‐Warmerdam, Judith R. Kroep, Hans Marten Hazelbag, Gerrit‐Jan Liefers, Marieke E. Straver, Wilma E. Mesker   +8 more
wiley   +1 more source

Real-world outcome of neoadjuvant therapy with or without pembrolizumab for triple-negative breast cancer. [PDF]

Acta Oncol
Maunu M, Lähteenmaa J, Karihtala P, Tuohinen S, Laaksolilja J, Laaksolilja J, Ståhls A, Meretoja T, Mattson J.   +8 more
europepmc   +1 more source

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

International Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, Raffaella Griffo, Laura V. Klotz, Michael Allgäuer, Albrecht Stenzinger, Helge Bischoff, Marc A. Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel, Inka Zoernig, Felix J. F. Herth, Michael Thomas, Alexander Rölle, Hauke Winter, Axel Benner, Dirk Jaeger, Martin E. Eichhorn   +19 more
wiley   +1 more source

Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World Data. [PDF]

Cancers (Basel)
Blumenröther AK, Fang Y, El Saadany T, Ramelyte E, Hasan Ali O, Kündig T, Mihic-Probst D, Steiner S, Maurer A, Dummer R, Mangana J, Maul LV.   +11 more
europepmc   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Exploring Machine Learning Approaches for Decision Support in Neoadjuvant Therapy of Locally Advanced Rectal Cancer. [PDF]

Oncol Res
Dhar E, Kabir MA, Nadar DR, Kuo LJ, Jonnagaddala J, Huang Y, Uddin M, Syed-Abdul S.   +7 more
europepmc   +1 more source

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, EarlyView.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond

International Journal of Cancer, EarlyView.
Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia, Søren Kjær Petersen, Louise M. Guldbrandt, Troels H. Borch, Christina H. Ruhlmann, Rasmus Blechingberg Friis, Adam A. Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Eva Ellebaek, Marco Donia   +11 more
wiley   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source